Key result
Review outlines strategies to manage genitourinary infection risks with SGLT2 inhibitors.
Why the study?
Concerns regarding the heightened risk of genitourinary infections with SGLT2 inhibitors remain a significant barrier to their wider adoption despite their cardiovascular and renal benefits.
What is the risk of genitourinary tract infections associated with SGLT2 inhibitors in patients with cardiovascular disease?
What is the risk of genitourinary tract infections associated with SGLT2 inhibitors in patients with cardiovascular disease?
This review provides clinical practice considerations for managing the risk of genitourinary infections in patients taking SGLT2 inhibitors to ensure proper risk-benefit assessment and optimal utilization.
Answers are grounded in this paper and cite their sources.
Requires genitourinary infection risk management with SGLT2 inhibitors in cardiovascular patients; leaves open precise net benefit quantification.
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce adverse cardiovascular events in patients with type 2 diabetes mellitus, all-cause mortality, and heart failure hospitalization in patients with heart failure, as well as adverse renal outcomes. However, concerns regarding the heightened risk of genitourinary (GU) infections, particularly urinary tract infections, remain a significant barrier to their wider adoption. Addressing these misconceptions using existing evidence is needed to ensure proper risk-benefit assessment and optimal utilization of this efficacious therapy. This review aims to provide a balanced perspective on the evidence-based cardiovascular and renal benefits of SGLT2is and the associated risk of GU infections. We also summarize and propose clinical practice considerations for SGLT2i-associated GU infections focusing on patients with cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Kittipibul et al. (2024) conducted a review in Cardiovascular disease, heart failure, and type 2 diabetes mellitus. SGLT2 inhibitors was evaluated. SGLT2 inhibitors provide cardiovascular and renal benefits, and this review outlines clinical practice considerations for managing the associated risk of genitourinary infections.
Synapse has enriched 10 related papers. Consider them for comparative context: